German firm Boehringer Ingelheim and the Massachusetts-based biotech Epizyme have announced that they will collaborate on the development of novel small molecule inhibitors directed toward two previously unaddressed epigenetic targets as potential therapies for people with cancer, in a deal worth up to $300 million.